Enhanced recovery with paravertebral and transversus abdominis plane blocks in microvascular breast reconstruction by Guffey, Ryan et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2020 
Enhanced recovery with paravertebral and transversus abdominis 
plane blocks in microvascular breast reconstruction 
Ryan Guffey 
Grace Keane 
Austin Y. Ha 
Rajiv Parikh 
Elizabeth Odom 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Ryan Guffey, Grace Keane, Austin Y. Ha, Rajiv Parikh, Elizabeth Odom, Li Zhang, and Terence M. Myckatyn 
https://doi.org/10.1177/1178223420967365
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial  
4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without 
further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Breast Cancer: Basic and Clinical Research
Volume 14: 1–8
© The Author(s) 2020
Article reuse guidelines: 
sagepub.com/journals-permissions
DOI: 10.1177/1 782234 09673 5
Introduction
Autologous microvascular breast reconstruction is potentially 
associated with superior cosmetic results, patient satisfaction, and 
patient-reported quality of life relative to simpler methods.1,2 
However, it is historically associated with a longer initial recovery 
time and substantial postoperative pain.3,4 In the past IV patient-
controlled opioids were the mainstay of pain treatment. Our 
patients were kept in nothing by mouth (NPO) status, had a uri-
nary catheter, and remained on bedrest for over 24 hours after 
surgery. These conservative practices were adopted to maximize 
safety, but recent studies in this patient population have shown 
them to be associated with delayed recovery.5-12
In May 2014, we added regional anesthesia in the form of a 
T3 paravertebral block as a method to improve pain control and 
postoperative outcomes after abdominally based autologous 
microvascular breast reconstruction. This single intervention was 
associated with improved outcomes including less acute pain, a 
more rapid transition to oral opioids, and decreased hospital stay 
by a full day.13 Less than 2 years later we adopted a full enhanced 
recovery protocol (enhanced recovery after surgery [ERAS]) 
adapted from the University of Toronto’s experience with pedi-
cled flap reconstruction.11 This was done to both improve out-
comes and also standardize treatment as part of a randomized 
controlled trial on liposomal bupivacaine. The results of the trial 
did not support any benefits to using liposomal bupivacaine as 
part of an intraoperative transversus abdominis plane (TAP) 
block, but it did not directly examine the effects of the enhanced 
recovery protocol.14 This study compares the effects of the ERAS 
protocol ( June 2016-February 2018) to our traditional care with 
the addition of a paravertebral nerve block (May 2014-August 
2015). We hypothesized that the ERAS cohort would require less 
opioid pain medications and have improved markers of recovery.
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ABSTRACT
PuRPoSE: We have shown previously that a preoperative paravertebral nerve block is associated with improved postoperative recovery in 
microvascular breast reconstruction. The purpose of this study was to compare the outcomes of a complete enhanced recovery after sur-
gery (ERAS) protocol with complete regional anesthesia coverage to our traditional care with paravertebral block.
PATiEnTS And METhodS: This was a retrospective cohort study of 83 patients who underwent autologous breast reconstruction by 
T.M.M. between May 2014 and February 2018 at a tertiary academic center. Patients in the ERAS group were additionally administered 
acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), gabapentin, a transversus abdominis plane block (liposomal or plain bupi-
vacaine), and primarily oral opioids postoperatively. The patients were mobilized earlier with more rapid diet progression. All patients 
received a preoperative paravertebral block.
RESulTS: Forty-four patients in the ERAS cohort were compared with 39 retrospective controls. The 2 groups were similar with respect to 
demographics and comorbidities. The ERAS cohort required significantly less opioids (291 vs 707 mg oral morphine equivalent, P < .0001) 
with unchanged postoperative pain scores and a shorter time to oral only opioid use (16.0 vs 78.2 hours, P < .0001). Median length of stay 
(3.20 vs 4.62, P < .0001) and time to independent ambulation (1.86 vs 2.88, P < .0001) were also significantly decreased in the ERAS cohort. 
Liposomal bupivacaine use did not significantly affect the results (P ⩾ .2).
ConCluSionS: Implementation of a robust enhanced recovery protocol with complete regional anesthesia coverage was associated with 
significantly decreased opioid use despite unchanged pain scores, with improved markers of recovery including length of stay, time to oral 
only narcotics, and time to independent ambulation.
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Patients and Methods
Study design and population
This was a retrospective, single-surgeon, cohort study of 2 
groups of patients who underwent abdominally based autolo-
gous breast reconstruction by the senior author (T.M.M.) 
between May 2014 and February 2018. It was approved by the 
Institutional Review Board (#201601064) at Washington 
University in St. Louis. All patients underwent an abdominally 
based autologous microvascular free flap breast reconstruction 
at Barnes Jewish Hospital supplemented by a T3 thoracic para-
vertebral nerve block. The ERAS cohort was managed using a 
complete enhanced recovery protocol implemented as part of 
the “Analgesic Effects of Liposomal Bupivacaine Versus 
Bupivacaine Hydrochloride Administered as a Transversus 
Abdominis Plane Block After Abdominally Based Autologous 
Microvascular Breast Reconstruction—A Prospective, Single-
Blinded, Randomized Control Trial.”14 Cases completed 
between August 7, 2015, and June 10, 2016, were excluded due 
to phased implementation of the complete enhanced recovery 
protocol. STROBE guidelines were adhered to during all 
phases of this research.
Surgical techniques
All patients underwent immediate or delayed autologous 
microvascular reconstruction with muscle-sparing trans-
verse rectus abdominis myocutaneous (ms-TRAM), deep 
inferior epigastric perforator (DIEP), or superficial inferior 
epigastric artery (SIEA) flaps. Donor-site fascia was closed 
either primarily or with mesh reinforcement at the discre-
tion of T.M.M.
Historical controls (May 2014-August 2015)
This cohort of patients was managed traditionally with the 
goal of minimizing potential damage to the flap in the early 
postoperative period and allowing for rapid safe return to the 
operating room if necessary (Supplemental Figure 1). Patients 
were kept in NPO status for 36 hours after surgery on bedrest 
with a urinary catheter and pain managed primarily by hydro-
morphone patient-controlled analgesia (PCA). Ambulation to 
chair was allowed and the diet was advanced to clear liquids on 
the second postoperative day. The urinary catheter and PCA 
were discontinued as tolerated on postoperative day 3. 
Preemptive analgesia consisted of preoperative ultrasound-
guided parasagittal approach T3 paravertebral blocks with 
15 mL of 0.5% bupivacaine injected per side for analgesia to 
the chest wound and subcutaneous infiltration of bupivacaine 
to the abdominal wound at the end of the case. Some of the 
traditionally accepted ERAS components were already in 
place during this cohort including preadmission counseling on 
expectations, venous thromboembolism prophylaxis, antimi-
crobial prophylaxis, nausea and vomiting prophylaxis, flap 
monitoring, a nerve block to the breast wound in the form of 
a paravertebral block, and standardized discharge criteria. The 
benefits of the paravertebral block in this patient population 
were studied previously.13
ERAS care ( June 2016-February 2018)
Our ERAS protocol includes almost all expected major compo-
nents including preadmission counseling on expectations, 
reduced perioperative fasting, venous thromboembolism proph-
ylaxis, antimicrobial prophylaxis, nausea and vomiting prophy-
laxis, multimodal analgesia to decrease opioid requirements, 
nerve blocks to all surgical wounds, early removal of lines, tubes, 
and drains, early feeding, early mobilization, flap monitoring, 
and standardized discharge criteria (Figure 1, Supplemental 
Figure 2).14,15 Intraoperative intravenous fluid administration 
was managed traditionally per the discretion of the anesthesia 
team. Their long-standing goals for these cases are to adminis-
ter crystalloid or colloid as needed to maintain mean arterial 
pressure greater than 80% of preoperative values and greater 
than 60 mm Hg without pressor administration. We believe that 
reduced IV fluid use could be associated with unacceptably low 
intraoperative blood pressure based on our prior experience 
with attempting to reduce intraoperative IV fluid in this patient 
population as well as recently published research.16
A complex standardized multimodal analgesia protocol was 
adopted with the goal of decreasing postoperative pain and 
patient request for opioid use. In addition to preoperative para-
vertebral blocks, scheduled acetaminophen 1000 mg QID, 
celecoxib 200 mg BID, oxycontin 10 mg BID, and gabapentin 
300 mg QHS were administered pre- and postoperatively. An 
intraoperative TAP block was administered with either 266 mg 
of liposomal bupivacaine or 75 mg of conventional bupivacaine 
under direct visualization to the T6-L1 intercostal levels imme-
diately prior to closure of the transverse abdominal incision as 
further described in the liposomal bupivacaine trial.14 We have 
previously shown there were no differences regarding pain con-
trol or any major outcome between liposomal bupivacaine or 
conventional bupivacaine in this cohort.14 On postoperative day 
(POD) zero, 1 mg of hydromorphone IV was made available 
every hour for rescue analgesia. Beginning with POD 1, 5 to 
10 mg of oral oxycodone was offered every 3 hours as well as 
0.5 mg of hydromorphone IV every hour as needed for break-
through pain. Nausea was preemptively controlled with scopola-
mine patches, intraoperative dexamethasone, and ondansetron. 
Patients were encouraged to get out of bed to a chair on POD 1, 
ambulate with assistance on POD 2, and ambulate indepen-
dently on POD 3. The goal discharge date was the morning of 
POD 3. Discharge criteria included reassuring flap exams by 
physician staff, adequate pain control on oral medications, ability 
to urinate spontaneously and to ambulate independently with 
waist flexed if needed to minimize tension, as well as tolerance of 
preoperative diet with return of bowel function.
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Data collection and outcome measures
Baseline patient demographic and clinical variables included 
age, race, body mass index (BMI), American Society of 
Anesthesiology (ASA) classification, preoperative opioid use, 
and comorbidities. Baseline data was pulled directly from a 
detailed history taken by the Center for Preoperative 
Assessment and Planning at Barnes Jewish Hospital. Pathologic 
variables included breast cancer side, history of chemotherapy, 
radiation, and mastectomy type. Reconstructive variables 
included laterality, timing of reconstruction, flap type, and 
mode of abdominal fascia closure. Complications and return 
trips to the operating room were also tabulated.
The primary outcome of this review is the total intra- and 
postoperative opioid consumption calculated in oral morphine 
equivalents. Secondary outcome measures are patient-reported 
numerical rating scale (NRS) pain scores at 2, 12, 24, 48, and 
72 hours postoperatively, duration of admission, amount of 
antiemetic use, time to urinary catheter removal, time to inde-
pendent ambulation, and time to oral only narcotics.
Statistical analyses
Our baseline data and demographics were compared with 
Fisher exact test, Student’s t test, or Mann-Whitney U test 
when appropriate. Normality was assessed using the Shapiro-
Wilk test and QQ plots (SPSS Statistics for Windows, 
Version 24.0. Armonk, NY: IBM Corp). Our primary out-
come and most secondary outcomes were analyzed with the 
Mann-Whitney U test due to skewed results distributions. To 
better characterize the duration of admission data, a Kaplan-
Meier analysis was also performed (Graphpad Prism 7 for 
Windows San Diego, CA). No adjustments were made due to 
near-perfect matching of baseline characteristics that are 
known to affect postoperative pain.
Results
Patient population
From June 2016 through March 2018, 70 patients who under-
went abdominally based microvascular breast reconstruction 
after mastectomy were enrolled in “The Analgesic Effects of 
Liposomal Bupivacaine Versus Bupivacaine Hydrochloride 
Administered as a Transversus Abdominis Plane Block After 
Abdominally Based Autologous Microvascular Breast 
Reconstruction—A Prospective, Single-Blinded, Randomized 
Control Trial.” Forty-four patients, or 22 in each group, com-
pleted the study. These patients comprise the ERAS cohort of 
this study. Ten patients had their surgeries scheduled after the 
trial closed. Eight were deemed ineligible because they were 
later found to take preoperative narcotics daily, deviated signifi-
cantly from the enhanced recovery protocol, or developed recur-
rent disease prior to surgery. Four patients withdrew their 
consent and another 4 patients had missing data. In total, 83 
patients are included in this study. A total of 39 patients 
who underwent abdominally based microvascular breast recon-
struction after mastectomy between May 2014 and August 
2015 were consecutively reviewed as retrospective controls. No 
ERAS Traditional
HYDRATION/ DIET –   12oz Water or carbohydrate drink at 5AM 
before surgery
–  NPO until POD 1
–  Saline lock IV POD 2
–   NPO after midnight  before surgery
–  NPO until POD 2
–  Continuous IV fluids until POD 4
ANALGESIA –  T3 Paravertebral block preoperatively
–   Transversus abdominis plane block before  
extubation
–  No PCA
–   Acetaminophen + NSAID + gabapentin + 
Oxycontin scheduled before and after surgery 
until discharge
–  PRN Oxycodone and hydromorphone
–   T3 Paravertebral block preoperatively
–   PCA until POD 3
–   Hydrocodone/acetaminophen POD3
OTHER MEDICATIONS –  Antibiotic
–   Dexamethasone + ondansetron intraoperatively
–   Ondansetron + enoxaparin + Docusate  
postoperatively
–  Antibiotic
–   Dexamethasone + Ondansetron  
intraoperatively
–   Ondansetron + Enoxaparin +  
Docusate postoperatively
FLAP CARE –   Flap checks Q1 hr POD0, Q2h POD1, Q4h 
POD 3
–   Flap checks Q1 hr POD0, Q2h POD1, 
Q4h POD 3
URINARY CATHETER –  Removed POD 1 –  Removed POD 3
AMBULATION –  Out of bed POD 1 –  Out of bed POD 2
Figure 1. Comparison of ERAS to traditional care.
ERAS indicates enhanced recovery after surgery; NPO, nothing by mouth; NSAID, non-steroidal anti-inflammatory drug; PCA, patient-controlled analgesia; POD, 
postoperative day; PRN, as needed; Q, dosed every.
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patients were excluded. There were no missing data for any out-
come measures on included patients.
Baseline characteristics
The 2 groups were similar with respect to age, race, ASA score, 
BMI, preoperative opioid use, comorbidities, and breast cancer 
laterality (Table 1). There was also no statistically significant 
difference between the 2 groups regarding reconstruction timing, 
donor type (ie, DIEP/ms-TRAM/SIEA), donor-site closure 
method, case duration, or complications (Table 2). Complications 
were recorded if there was a need for bedside intervention or 
return to the operating room. Despite not deliberately matching 
the groups, the 2 cohorts are effectively matched for all risk fac-
tors for increased postoperative pain (age, BMI, ASA score, opi-
oid use, case duration, chemotherapy, and radiation history).
Table 1. Baseline demographic and clinical variables.
HISTORICAL (N = 39) ERAS (N = 44) P
Age 49 (9.0) 49 (9.5) .82
Race
 White 32 (82%) 39 (89%) .53
 Non-white 7 (18%) 5 (11%)  
Weight (kg) 78.8 (13.4) 78.6 (13.5) .94
BMI 29.2 (4.8) 28.6 (4.5) .59
ASA Score (IQR) 2 (0) 2 (0) .49
Home opioid use preoperatively 6 (15%) 5 (11%) .75
DM 4 (10%) 1 (2%) .18
GERD 11 (28%) 15 (34%) .64
HTN 10 (26%) 5 (11%) .15
Vascular disease 3 (8%) 0 (0%) .10
Valvular disease 3 (8%) 2 (4%) .66
CAD 0 (0%) 0 (0%) —
Arrhythmia 0 (0%) 1 (2%) 1.00
CHF 0 (0%) 0 (0%) —
Asthma or COPD 6 (15%) 5 (11%) .75
OSA 2 (5%) 5 (11%) .44
CKD 0 (0%) 1 (2%) 1.00
Stroke history 0 (0%) 0 (0%) —
PONV history 11 (28.2) 13 (29.5) 1.00
Chemotherapy history 26 (67%) 34 (77%) .33
Radiation history 23 (59%) 27 (61%) 1.00
Breast cancer side
 Right 19 (48%) 22 (50%) .58
 Left 13 (33%) 10 (23%)  
 Bilateral 6 (15%) 8 (18%)  
 None 1 (3%) 4 (9%)  
Breast cancer surgery side
 Right 10 (26%) 14 (32%) .16
 Left 7 (18%) 2 (4%)  
 Bilateral 22 (56%) 28 (64%)  
Abbreviations: ASA, American Society of Anesthesiology; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; OSA, obstructive sleep 
apnea; CKD, chronic kidney disease; PONV, postoperative nauesa and vomiting; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ERAS, enhanced 
recovery after surgery; GERD, gastroesophageal reflux disease; HTN, hypertension; IQR, interquartile range; SD, standard deviation.
Values are presented as mean (SD), median (IQR), or n (n%).
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Table 2. Baseline reconstructive variables.
HISTORICAL (N = 39) ERAS (N = 44) P
Reconstruction side
 Right 10 (26%) 14 (32%) .16
 Left 7 (18%) 2 (4%)  
 Bilateral 22 (56%) 28 (64%)  
Delayed reconstruction 33 (85%) 36 (82%) .70
Right abdomen donor type
 DIEP 24 (62%) 26 (59%) 1.00
 MS-TRAM 8 (20%) 9 (20%)  
 SIEA 1 (3%) 1 (2%)  
 TRAM 0 (0%) 1 (2%)  
 Left only 6 (15%) 7 (16%)  
Left abdomen donor type
 DIEP 23 (59%) 23 (52%) .51
 MS-TRAM 5 (13%) 10 (23%)  
 SIEA 0 (0%) 2 (4%)  
 TRAM 1 (3%) 1 (3%)  
 Right only 10 (26%) 8 (18%)  
Right abdomen closure
 Primary closure 27 (69%) 26 (59%) .57
 Mesh 5 (13%) 9 (20%)  
 No fascial closure necessary 7 (18%) 9 (20%)  
Left abdomen Closure
 Primary closure 18 (46%) 24 (54%) .77
 Mesh 11 (28%) 10 (23%)  
 No fascial closure necessary 10 (26%) 10 (23%)  
Anesthesia case duration (hours) 9.8 (2.0) 9.4 (1.7) .33
Surgical complications
 Venous congestion 1 (3%) 2 (4%) 1.00
 Partial flap loss/flap necrosis 2 (5%) 2 (4%) 1.00
 Arterial insufficiency 0 (0%) 2 (4%) .50
 Abdominal wound dehiscence 4 (10%) 0 (0%) .05
 Donor-site seroma 1 (3%) 0 (0%) .47
 Donor-site hematoma 0 (0%) 1 (2%) 1.00
 Complete flap loss 0 (0%) 0 (0%) 1.00
 Breast hematoma 0 (0%) 0 (0%) 1.00
 Abdominal cellulitis 1 (3%) 0 (0%) 1.00
 Total 9 (23%) 7 (16%) .58
Abbreviations: DIEP, deep inferior epigastric perforator; ERAS, enhanced recovery after surgery; MS-TRAM, muscle-sparing transverse rectus abdominis muscle; SIEA, 
superficial inferior epigastric artery; TRAM, transverse rectus abdominis muscle.
Values are presented as mean (SD) or n (n%).
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Outcomes
The median total opioid consumption in the ERAS group 
(291 mg) was significantly decreased when compared with his-
torical controls (707 mg, P < .0001) (Table 3). Opioid use also 
revealed consistently significant between-group differences. 
This effect was not associated with time when a segmental 
regression analysis was performed for the historical and ERAS 
periods (r2 = 0.006, P = .32, r2 = 0.009, P = .27). Despite mark-
edly decreased opioid usage, pain scores were not significantly 
different between groups. As one would expect with a protocol 
that discourages IV PCA usage, time to oral only narcotic use 
was significantly decreased by over 2 days (78.2 vs 16.0 hours, 
P < .0001). Median total opioid use was significantly higher in 
patients with delayed reconstruction (443 vs 339 mg, P = .045). 
There were no other significant differences regarding recon-
struction timing.
The ERAS protocol’s attempts to encourage ambulation, 
remove the urinary catheter earlier, and support earlier dis-
charge home were successful. Patients were able to indepen-
dently ambulate 1 full day earlier as the protocol suggested 
(1.86 vs 2.88 days, P < .0001). The duration of the urinary 
catheter was significantly reduced from 3.24 days to 1.05 days 
(P < .0001). Patients in the ERAS group were able to be dis-
charged more than 1 full day earlier (3.20 vs 4.62 days, 
P < .0001). A Kaplan-Meier analysis best characterizes this 
(Figure 2, P < .0001). Liposomal bupivacaine or plain bupiv-
acaine usage did not affect any of the above results (P ⩾ .2).14 
There was no significant difference with respect to antiemetic 
usage. This study was not powered to comment on differences 
Table 3. Outcomes.
HISTORICAL (N = 39) ERAS (N = 44) P
Opioid usage (oral morphine equivalents, mg)
 Intraoperative 145 (70) 102.5 (64) .001
 PACU and Floor 525 (370) 161 (166) <.0001
 PACU and Floor per day 129 (62) 62 (52) <.0001
 Total 707 (430) 291 (220) <.0001
Pain scores
 2 hours 3 (5) 2 (5) .64
 12 hours 2 (5) 0.5 (3)  
 24 hours 4 (5) 2 (5)  
 48 hours 3 (3) 2 (4)  
 72 hours 2 (4) 1.5 (4)  
Time to oral only narcotics (hours) 78.2 (29) 16.0 (16) <.0001
Duration of admission 4.62 (1.0) 3.20 (1.0) <.0001
Duration of catheter 3.24 (0.9) 1.05 (0.8) <.0001
Time to ambulation 2.88 (1.1) 1.86 (0.9) <.0001
Antiemetic doses
 PACU 0 (0) 0 (0) .60
 Floor 0 (2) 0 (3) .72
 Total 0 (2) 0 (3) .92
Abbreviations: ANOVA, analysis of variance; ERAS, enhanced recovery after surgery; IQR, interquartile range; PACU, postoperative acute care unit.
Values are presented as median (IQR).
Mann-Whitney U or General Linear Model Repeated-Measures ANOVA (Pilal’s Trace) used where appropriate.
P < .007 is considered significant based on 7 concurrent comparisons (Bonferroni).
Figure 2. Duration of admission.
ERAS indicates enhanced recovery after surgery.
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in complication rates. There were no complications attributed 
to the paravertebral or TAP blocks.
Discussion
The results of this study demonstrate that implementation of the 
ERAS protocol was associated with unchanged pain scores 
despite significantly reduced opioid consumption. Efforts to 
improve the pace of recovery were successful with greater than 
1 day decreases in time to oral only narcotics, duration of urinary 
catheter, time to independent ambulation, and duration of admis-
sion. These results are consistent with the success of other ERAS 
protocols previously implemented in breast reconstruction sur-
gery. Our patients’ median NRS pain scores (0.5-2) and median 
3.2 day duration of admission were similar to the lowest reported 
by other comparable studies.5-7,9,12,17 A recent nationwide review 
by Billig of the national inpatient sample showed a median length 
of stay of 4 days (interquartile range [IQR], 3-5).18
We believe that analgesia to the chest wound is required for 
maximum benefit. Four other ERAS protocols without regional 
analgesia to the chest reported potentially higher median dura-
tions of admission: Bonde (6.2 days), Astanahe (4.8 days), 
Alfonso (4.0 days), and Bardorf (3.9 days).5-7,17 Kouzantis 
et al12 presented a protocol with a median duration of admis-
sion of 3.0 days without regional anesthesia to the chest wall, 
but used IV ketamine, methadone, and a lidocaine infusion 
started intraoperatively and continued for 24 hours postopera-
tively. These additional nonopioid methods of pain control may 
be an alternative to nerve block for chest wall pain. However, a 
lidocaine infusion with a bolus shortly after a TAP block as 
administered Kouzantis’ study could potentially increase the 
risk of intraoperative local anesthetic toxicity. It may be safer to 
delay initiation of the lidocaine infusion protocol for 4 hours 
after the TAP block or avoid the initial bolus. Similarly, it is 
important to separate abdominal and chest wall blocks by the 
most time possible to allow for higher dosage of local anes-
thetic without putting the patient at risk for local anesthetic 
toxicity. This is why in our protocol the paravertebral block is 
administered preoperatively and the abdominal TAP block is 
placed at the end of the case, over 6 hours apart. After 6 hours, 
the plasma level of local anesthetic is reduced by over 50%.19
Other potential alternatives to the paravertebral block for 
analgesia could include intercostal, erector spinae, or serratus 
anterior plane blocks.20-22 We perform paravertebral analgesia 
due to its well described benefits in the literature and availability 
of an experienced dedicated regional anesthesia team to perform 
the nerve block preoperatively. Paravertebral blocks, IV lidocaine 
infusions, and continuous local anesthetic wound infusions have 
been associated with decreased acute and chronic postoperative 
pain in multiple breast surgery studies.23 Of these, paravertebral 
blocks are the only non-continuous option. They also have the 
advantage of not affecting intraoperative blood pressure.15
It is our opinion that ERAS in microvascular breast 
reconstruction should be the standard of care. Our study is 
consistent with a recent meta-analysis that found significant 
improvement in opioid use and length of stay with no increase 
in complications.24,25 With paravertebral as well as TAP anal-
gesia, our protocol was unique in accomplishing this without 
continuous infusions, and expensive or high-risk medications. 
This protocol allowed us to consistently avoid using PCA. The 
PCA tethers patients to an IV pole if they would like to walk 
and still have pain relief. Multimodal analgesia without a PCA 
and urinary catheter allows patients to ambulate much more 
comfortably and effectively. Long-acting pain medications also 
improve sleep quality. We believe these are the reasons our 
patients were able to recover more quickly. It appears subjec-
tively that our patients are more active and closer to their base-
line activity level on postoperative day 3 with the ERAS 
protocol than they were on day 5 before we initiated ERAS.
There have been multiple updates to the literature since 
we created our ERAS protocol. In the future, we are consider-
ing stopping the oxycontin after the evening POD 0 dose, 
increasing the dexamethasone dose to 8 mg, and omitting the 
gabapentin26 unless taken at home.
We acknowledge there are limitations with this study. 
Although the data from the ERAS group was collected pro-
spectively, the historical data was collected retrospectively. As 
the prospective data was collected as part of a randomized con-
trolled trial, there were exclusion criteria for the prospective 
portion of this study that were not present for the retrospective 
cohort. Fortunately, there were no significant differences 
regarding baseline characteristics as shown in Table 1.
There are many factors that can influence recovery that are 
not easily studied in a retrospective cohort design. An individ-
ual’s frailty, anatomical variability, vascular status, and social 
factors including family support, and willingness to comply 
with treatment may have dramatic effects on one’s speed of 
recovery. We have attempted to include all relevant medical 
history, but retrospective results do not account for improve-
ments in care with time. We have attempted to address this 
with our non-significant segmental regression analysis and 
near perfectly matched groups. All cases were also performed 
by the same experienced surgeon, eliminating another source of 
variability. Our results are not generalizable to all settings.
Conclusions
In this cohort study, implementation of a robust enhanced 
recovery protocol with plain or liposomal bupivacaine was 
associated with significantly decreased opioid use despite 
unchanged pain scores, with improved markers of recovery 
including length of stay, time to oral only narcotics, and time to 
independent ambulation.
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